[Adjuvant chemo-immunotherapy with VBL + INF in renal carcinoma. Long-term results]

Authors show results of adjuvant chemoimmunotherapeutic approach (0, 10 mg/kg Vinblastine every three weeks plus INF - alpha 2a - and INF - alpha 2b in a dose of 3 x 10(6) U.I. three times a week) adopted after radical nephrectomy in 45 patients with renal carcinoma (p. T3/4. NO.MO; pT3/4. N+/O. M+/O). The treatment may be summed up: 1# to effect a regression of metastasis that is not possible surgically to remove either because of its location or extent; 2) to limit micrometastatic diffusion in patients with N+. 3) It is important to perform this treatment in stage T3 N0M0 where clinical progression is (21.1%) in our group.